24.04.2020

Bayer joins the call for the continuity of life-saving malaria prevention measures in the wake of the coronavirus pandemic

- 1,100 people die from malaria everyday, taking the life of one child every two minutes.

- Malaria is a preventable and treatable disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes.

Johannesburg, April 24, 2020- As the resilience of the most robust health systems around the world continues to be tested in the wake of the coronavirus pandemic, this World Malaria Day, Bayer encourages countries especially vulnerable to malaria, to ensure the continuity of malaria prevention and control measures in support of the appeal from the World Health Organisation (WHO).

 

Nearly half the world’s population remains at risk from malaria infection and in 2018, it led to a staggering 405,000 deaths worldwide, 94% of which occurred in Africa.  Considering these numbers, it is critical that programmes to prevent the disease continue in regions such as sub-Saharan Africa, where populations are most vulnerable and health infrastructures are oftentimes fragile.

 

Dr. Jacqueline Applegate, President of the unit working in vector-borne disease prevention at Bayer, says, “As the world’s attention focuses on COVID-19, our efforts to eradicate malaria must remain a priority as it is in times of health and economic crises that diseases have the potential to resurge.  We simply cannot let our guard down if we are to protect the millions at high risk from malaria, many of whom are farmers, and stop the cycle of hunger and poverty. For Bayer malaria has been – and will continue to be – high on the agenda.”

 

By ensuring access to core malaria prevention measures the strain on health systems can be reduced, allowing more availability for treatment of COVID-19 cases. Since 2000, the coordinated battle against malaria has culminated in a 60% reduction of malaria-related deaths saving close to seven million lives. This year, COVID-19 is threatening to disrupt malaria prevention and treatment programmes and we need to ensure that progress is not lost.

“Today, more than ever before, we truly appreciate the immensity and global impact of infectious diseases. They don’t respect borders and require governments, scientists and academics, innovators, NGO’s and corporations to work together.” emphasised Dr. Applegate.

 

Bayer is continuing to support our partners to implement vector control by ensuring our production sites, supply chains and logistics continue to bring life-saving malaria tools to those most in need. Bayer also continues to invest in research and development to identify new transformative tools to fight against the disease.

 

World Malaria Day, marked each year on 25 April, is an occasion to highlight the need for continued investment and sustained political commitment for malaria prevention and control.

 

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the sametime, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.co.za .

 

Contact:

 

Tasniem Patel

Mobile +27 82 8732423

Head of Communications for Southern Africa

Email: tasniem.patel@bayer.com

 

 

 

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.